Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 42 entries
Sorted by: Best Match Show Resources per page
Sublocalization of smallest common regions of deletion on chromosome 17q12-q23 in sporadic primary breast-tumors.

Oncology reports

Champeme M, Mazoyer S, Stoppalyonnet D, Bieche I, Ithier G, Sobol H, Nogues C, Lidereau R.
PMID: 21597825
Oncol Rep. 1995 Sep;2(5):825-31. doi: 10.3892/or.2.5.825.

Frequent loss of heterozygosity (LOH) on the long arm of chromosome 17 has been described in breast tumor DNAs by a number of groups, and recent fine genetic mapping and cloning of an inherited breast-ovarian cancer susceptibility locus (BRCA1)...

Cite
Champeme M, Mazoyer S, Stoppalyonnet D, et al. Sublocalization of smallest common regions of deletion on chromosome 17q12-q23 in sporadic primary breast-tumors. Oncol Rep. 1995;2(5):825-31doi: 10.3892/or.2.5.825.
Champeme, M., Mazoyer, S., Stoppalyonnet, D., Bieche, I., Ithier, G., Sobol, H., Nogues, C., & Lidereau, R. (1995). Sublocalization of smallest common regions of deletion on chromosome 17q12-q23 in sporadic primary breast-tumors. Oncology reports, 2(5), 825-31. https://doi.org/10.3892/or.2.5.825
Champeme, M, et al. "Sublocalization of smallest common regions of deletion on chromosome 17q12-q23 in sporadic primary breast-tumors." Oncology reports vol. 2,5 (1995): 825-31. doi: https://doi.org/10.3892/or.2.5.825
Champeme M, Mazoyer S, Stoppalyonnet D, Bieche I, Ithier G, Sobol H, Nogues C, Lidereau R. Sublocalization of smallest common regions of deletion on chromosome 17q12-q23 in sporadic primary breast-tumors. Oncol Rep. 1995 Sep;2(5):825-31. doi: 10.3892/or.2.5.825. PMID: 21597825.
Copy Download .nbib Format: NLM
Recurrent .

Kidney international reports

Gueguen L, Delaval R, Blanluet M, Sartelet H, Leou S, Dubois d'Enghien C, Golmard L, Stoppa-Lyonnet D, Testevuide P, Faguer S.
PMID: 34386670
Kidney Int Rep. 2021 May 21;6(8):2207-2211. doi: 10.1016/j.ekir.2021.05.010. eCollection 2021 Aug.

No abstract available.

Cite
Gueguen L, Delaval R, Blanluet M, et al. Recurrent . Kidney Int Rep. 2021;6(8):2207-2211doi: 10.1016/j.ekir.2021.05.010.
Gueguen, L., Delaval, R., Blanluet, M., Sartelet, H., Leou, S., Dubois d'Enghien, C., Golmard, L., Stoppa-Lyonnet, D., Testevuide, P., & Faguer, S. (2021). Recurrent . Kidney international reports, 6(8), 2207-2211. https://doi.org/10.1016/j.ekir.2021.05.010
Gueguen, Lorraine, et al. "Recurrent ." Kidney international reports vol. 6,8 (2021): 2207-2211. doi: https://doi.org/10.1016/j.ekir.2021.05.010
Gueguen L, Delaval R, Blanluet M, Sartelet H, Leou S, Dubois d'Enghien C, Golmard L, Stoppa-Lyonnet D, Testevuide P, Faguer S. Recurrent . Kidney Int Rep. 2021 May 21;6(8):2207-2211. doi: 10.1016/j.ekir.2021.05.010. eCollection 2021 Aug. PMID: 34386670; PMCID: PMC8344115.
Copy Download .nbib Format: NLM
Tumor .

Gynecologic oncology reports

Villy MC, Masliah-Planchon J, Melaabi S, Trabelsi Grati O, Girard E, Bataillon G, Vincent-Salomon A, Le Gall J, Golmard L, Stoppa-Lyonnet D, Bieche I, Colas C.
PMID: 34541275
Gynecol Oncol Rep. 2021 Sep 02;37:100855. doi: 10.1016/j.gore.2021.100855. eCollection 2021 Aug.

OBJECTIVE: Tumors harboring a METHODS: We describe seven tumors harboring a RESULTS: Four of the five tumors selected because of multiple CONCLUSIONS: Tumor

Cite
Villy MC, Masliah-Planchon J, Melaabi S, et al. Tumor . Gynecol Oncol Rep. 2021;37:100855doi: 10.1016/j.gore.2021.100855.
Villy, M. C., Masliah-Planchon, J., Melaabi, S., Trabelsi Grati, O., Girard, E., Bataillon, G., Vincent-Salomon, A., Le Gall, J., Golmard, L., Stoppa-Lyonnet, D., Bieche, I., & Colas, C. (2021). Tumor . Gynecologic oncology reports, 37100855. https://doi.org/10.1016/j.gore.2021.100855
Villy, M-C, et al. "Tumor ." Gynecologic oncology reports vol. 37 (2021): 100855. doi: https://doi.org/10.1016/j.gore.2021.100855
Villy MC, Masliah-Planchon J, Melaabi S, Trabelsi Grati O, Girard E, Bataillon G, Vincent-Salomon A, Le Gall J, Golmard L, Stoppa-Lyonnet D, Bieche I, Colas C. Tumor . Gynecol Oncol Rep. 2021 Sep 02;37:100855. doi: 10.1016/j.gore.2021.100855. eCollection 2021 Aug. PMID: 34541275; PMCID: PMC8435919.
Copy Download .nbib Format: NLM
Survey on Physicians' Knowledge and Training Needs in Genetic Counseling in Germany.

Breast care (Basel, Switzerland)

Dick J, Aue V, Wesselmann S, Brédart A, Dolbeault S, Devilee P, Stoppa-Lyonnet D, Schmutzler RK, Rhiem K.
PMID: 34602945
Breast Care (Basel). 2021 Aug;16(4):389-395. doi: 10.1159/000511136. Epub 2020 Nov 04.

BACKGROUND: In recent years, germline testing of women with a risk of developing breast and ovarian cancer has increased rapidly. This is due to lower costs for new high-throughput sequencing technologies and the manifold preventive and therapeutic options for...

Cite
Dick J, Aue V, Wesselmann S, et al. Survey on Physicians' Knowledge and Training Needs in Genetic Counseling in Germany. Breast Care (Basel). 2020;16(4):389-395doi: 10.1159/000511136.
Dick, J., Aue, V., Wesselmann, S., Brédart, A., Dolbeault, S., Devilee, P., Stoppa-Lyonnet, D., Schmutzler, R. K., & Rhiem, K. (2021). Survey on Physicians' Knowledge and Training Needs in Genetic Counseling in Germany. Breast care (Basel, Switzerland), 16(4), 389-395. https://doi.org/10.1159/000511136
Dick, Julia, et al. "Survey on Physicians' Knowledge and Training Needs in Genetic Counseling in Germany." Breast care (Basel, Switzerland) vol. 16,4 (2021): 389-395. doi: https://doi.org/10.1159/000511136
Dick J, Aue V, Wesselmann S, Brédart A, Dolbeault S, Devilee P, Stoppa-Lyonnet D, Schmutzler RK, Rhiem K. Survey on Physicians' Knowledge and Training Needs in Genetic Counseling in Germany. Breast Care (Basel). 2021 Aug;16(4):389-395. doi: 10.1159/000511136. Epub 2020 Nov 04. PMID: 34602945; PMCID: PMC8436720.
Copy Download .nbib Format: NLM
Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.

Nature communications

Coignard J, Lush M, Beesley J, O'Mara TA, Dennis J, Tyrer JP, Barnes DR, McGuffog L, Leslie G, Bolla MK, Adank MA, Agata S, Ahearn T, Aittomäki K, Andrulis IL, Anton-Culver H, Arndt V, Arnold N, Aronson KJ, Arun BK, Augustinsson A, Azzollini J, Barrowdale D, Baynes C, Becher H, Bermisheva M, Bernstein L, Białkowska K, Blomqvist C, Bojesen SE, Bonanni B, Borg A, Brauch H, Brenner H, Burwinkel B, Buys SS, Caldés T, Caligo MA, Campa D, Carter BD, Castelao JE, Chang-Claude J, Chanock SJ, Chung WK, Claes KBM, Clarke CL, Collée JM, Conroy DM, Czene K, Daly MB, Devilee P, Diez O, Ding YC, Domchek SM, Dörk T, Dos-Santos-Silva I, Dunning AM, Dwek M, Eccles DM, Eliassen AH, Engel C, Eriksson M, Evans DG, Fasching PA, Flyger H, Fostira F, Friedman E, Fritschi L, Frost D, Gago-Dominguez M, Gapstur SM, Garber J, Garcia-Barberan V, García-Closas M, García-Sáenz JA, Gaudet MM, Gayther SA, Gehrig A, Georgoulias V, Giles GG, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Greene MH, Guénel P, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hall P, Hamann U, Harrington PA, Hart SN, He W, Hogervorst FBL, Hollestelle A, Hopper JL, Horcasitas DJ, Hulick PJ, Hunter DJ, Imyanitov EN, Jager A, Jakubowska A, James PA, Jensen UB, John EM, Jones ME, Kaaks R, Kapoor PM, Karlan BY, Keeman R, Khusnutdinova E, Kiiski JI, Ko YD, Kosma VM, Kraft P, Kurian AW, Laitman Y, Lambrechts D, Le Marchand L, Lester J, Lesueur F, Lindstrom T, Lopez-Fernández A, Loud JT, Luccarini C, Mannermaa A, Manoukian S, Margolin S, Martens JWM, Mebirouk N, Meindl A, Miller A, Milne RL, Montagna M, Nathanson KL, Neuhausen SL, Nevanlinna H, Nielsen FC, O'Brien KM, Olopade OI, Olson JE, Olsson H, Osorio A, Ottini L, Park-Simon TW, Parsons MT, Pedersen IS, Peshkin B, Peterlongo P, Peto J, Pharoah PDP, Phillips KA, Polley EC, Poppe B, Presneau N, Pujana MA, Punie K, Radice P, Rantala J, Rashid MU, Rennert G, Rennert HS, Robson M, Romero A, Rossing M, Saloustros E, Sandler DP, Santella R, Scheuner MT, Schmidt MK, Schmidt G, Scott C, Sharma P, Soucy P, Southey MC, Spinelli JJ, Steinsnyder Z, Stone J, Stoppa-Lyonnet D, Swerdlow A, Tamimi RM, Tapper WJ, Taylor JA, Terry MB, Teulé A, Thull DL, Tischkowitz M, Toland AE, Torres D, Trainer AH, Truong T, Tung N, Vachon CM, Vega A, Vijai J, Wang Q, Wappenschmidt B, Weinberg CR, Weitzel JN, Wendt C, Wolk A, Yadav S, Yang XR, Yannoukakos D, Zheng W, Ziogas A, Zorn KK, Park SK, Thomassen M, Offit K, Schmutzler RK, Couch FJ, Simard J, Chenevix-Trench G, Easton DF, Andrieu N, Antoniou AC.
PMID: 33990587
Nat Commun. 2021 May 14;12(1):2986. doi: 10.1038/s41467-021-23162-4.

A Correction to this paper has been published: https://doi.org/10.1038/s41467-021-23162-4.

Cite
Coignard J, Lush M, Beesley J, et al. Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nat Commun. 2021;12(1):2986doi: 10.1038/s41467-021-23162-4.
Coignard, J., Lush, M., Beesley, J., O'Mara, T. A., Dennis, J., Tyrer, J. P., Barnes, D. R., McGuffog, L., Leslie, G., Bolla, M. K., Adank, M. A., Agata, S., Ahearn, T., Aittomäki, K., Andrulis, I. L., Anton-Culver, H., Arndt, V., Arnold, N., Aronson, K. J., Arun, B. K., Augustinsson, A., Azzollini, J., Barrowdale, D., Baynes, C., Becher, H., Bermisheva, M., Bernstein, L., Białkowska, K., Blomqvist, C., Bojesen, S. E., Bonanni, B., Borg, A., Brauch, H., Brenner, H., Burwinkel, B., Buys, S. S., Caldés, T., Caligo, M. A., Campa, D., Carter, B. D., Castelao, J. E., Chang-Claude, J., Chanock, S. J., Chung, W. K., Claes, K. B. M., Clarke, C. L., Collée, J. M., Conroy, D. M., Czene, K., Daly, M. B., Devilee, P., Diez, O., Ding, Y. C., Domchek, S. M., Dörk, T., Dos-Santos-Silva, I., Dunning, A. M., Dwek, M., Eccles, D. M., Eliassen, A. H., Engel, C., Eriksson, M., Evans, D. G., Fasching, P. A., Flyger, H., Fostira, F., Friedman, E., Fritschi, L., Frost, D., Gago-Dominguez, M., Gapstur, S. M., Garber, J., Garcia-Barberan, V., García-Closas, M., García-Sáenz, J. A., Gaudet, M. M., Gayther, S. A., Gehrig, A., Georgoulias, V., Giles, G. G., Godwin, A. K., Goldberg, M. S., Goldgar, D. E., González-Neira, A., Greene, M. H., Guénel, P., Haeberle, L., Hahnen, E., Haiman, C. A., Håkansson, N., Hall, P., Hamann, U., Harrington, P. A., Hart, S. N., He, W., Hogervorst, F. B. L., Hollestelle, A., Hopper, J. L., Horcasitas, D. J., Hulick, P. J., Hunter, D. J., Imyanitov, E. N., Jager, A., Jakubowska, A., James, P. A., Jensen, U. B., John, E. M., Jones, M. E., Kaaks, R., Kapoor, P. M., Karlan, B. Y., Keeman, R., Khusnutdinova, E., Kiiski, J. I., Ko, Y. D., Kosma, V. M., Kraft, P., Kurian, A. W., Laitman, Y., Lambrechts, D., Le Marchand, L., Lester, J., Lesueur, F., Lindstrom, T., Lopez-Fernández, A., Loud, J. T., Luccarini, C., Mannermaa, A., Manoukian, S., Margolin, S., Martens, J. W. M., Mebirouk, N., Meindl, A., Miller, A., Milne, R. L., Montagna, M., Nathanson, K. L., Neuhausen, S. L., Nevanlinna, H., Nielsen, F. C., O'Brien, K. M., Olopade, O. I., Olson, J. E., Olsson, H., Osorio, A., Ottini, L., Park-Simon, T. W., Parsons, M. T., Pedersen, I. S., Peshkin, B., Peterlongo, P., Peto, J., Pharoah, P. D. P., Phillips, K. A., Polley, E. C., Poppe, B., Presneau, N., Pujana, M. A., Punie, K., Radice, P., Rantala, J., Rashid, M. U., Rennert, G., Rennert, H. S., Robson, M., Romero, A., Rossing, M., Saloustros, E., Sandler, D. P., Santella, R., Scheuner, M. T., Schmidt, M. K., Schmidt, G., Scott, C., Sharma, P., Soucy, P., Southey, M. C., Spinelli, J. J., Steinsnyder, Z., Stone, J., Stoppa-Lyonnet, D., Swerdlow, A., Tamimi, R. M., Tapper, W. J., Taylor, J. A., Terry, M. B., Teulé, A., Thull, D. L., Tischkowitz, M., Toland, A. E., Torres, D., Trainer, A. H., Truong, T., Tung, N., Vachon, C. M., Vega, A., Vijai, J., Wang, Q., Wappenschmidt, B., Weinberg, C. R., Weitzel, J. N., Wendt, C., Wolk, A., Yadav, S., Yang, X. R., Yannoukakos, D., Zheng, W., Ziogas, A., Zorn, K. K., Park, S. K., Thomassen, M., Offit, K., Schmutzler, R. K., Couch, F. J., Simard, J., Chenevix-Trench, G., Easton, D. F., Andrieu, N., & Antoniou, A. C. (2021). Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature communications, 12(1), 2986. https://doi.org/10.1038/s41467-021-23162-4
Coignard, Juliette, et al. "Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers." Nature communications vol. 12,1 (2021): 2986. doi: https://doi.org/10.1038/s41467-021-23162-4
Coignard J, Lush M, Beesley J, O'Mara TA, Dennis J, Tyrer JP, Barnes DR, McGuffog L, Leslie G, Bolla MK, Adank MA, Agata S, Ahearn T, Aittomäki K, Andrulis IL, Anton-Culver H, Arndt V, Arnold N, Aronson KJ, Arun BK, Augustinsson A, Azzollini J, Barrowdale D, Baynes C, Becher H, Bermisheva M, Bernstein L, Białkowska K, Blomqvist C, Bojesen SE, Bonanni B, Borg A, Brauch H, Brenner H, Burwinkel B, Buys SS, Caldés T, Caligo MA, Campa D, Carter BD, Castelao JE, Chang-Claude J, Chanock SJ, Chung WK, Claes KBM, Clarke CL, Collée JM, Conroy DM, Czene K, Daly MB, Devilee P, Diez O, Ding YC, Domchek SM, Dörk T, Dos-Santos-Silva I, Dunning AM, Dwek M, Eccles DM, Eliassen AH, Engel C, Eriksson M, Evans DG, Fasching PA, Flyger H, Fostira F, Friedman E, Fritschi L, Frost D, Gago-Dominguez M, Gapstur SM, Garber J, Garcia-Barberan V, García-Closas M, García-Sáenz JA, Gaudet MM, Gayther SA, Gehrig A, Georgoulias V, Giles GG, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Greene MH, Guénel P, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hall P, Hamann U, Harrington PA, Hart SN, He W, Hogervorst FBL, Hollestelle A, Hopper JL, Horcasitas DJ, Hulick PJ, Hunter DJ, Imyanitov EN, Jager A, Jakubowska A, James PA, Jensen UB, John EM, Jones ME, Kaaks R, Kapoor PM, Karlan BY, Keeman R, Khusnutdinova E, Kiiski JI, Ko YD, Kosma VM, Kraft P, Kurian AW, Laitman Y, Lambrechts D, Le Marchand L, Lester J, Lesueur F, Lindstrom T, Lopez-Fernández A, Loud JT, Luccarini C, Mannermaa A, Manoukian S, Margolin S, Martens JWM, Mebirouk N, Meindl A, Miller A, Milne RL, Montagna M, Nathanson KL, Neuhausen SL, Nevanlinna H, Nielsen FC, O'Brien KM, Olopade OI, Olson JE, Olsson H, Osorio A, Ottini L, Park-Simon TW, Parsons MT, Pedersen IS, Peshkin B, Peterlongo P, Peto J, Pharoah PDP, Phillips KA, Polley EC, Poppe B, Presneau N, Pujana MA, Punie K, Radice P, Rantala J, Rashid MU, Rennert G, Rennert HS, Robson M, Romero A, Rossing M, Saloustros E, Sandler DP, Santella R, Scheuner MT, Schmidt MK, Schmidt G, Scott C, Sharma P, Soucy P, Southey MC, Spinelli JJ, Steinsnyder Z, Stone J, Stoppa-Lyonnet D, Swerdlow A, Tamimi RM, Tapper WJ, Taylor JA, Terry MB, Teulé A, Thull DL, Tischkowitz M, Toland AE, Torres D, Trainer AH, Truong T, Tung N, Vachon CM, Vega A, Vijai J, Wang Q, Wappenschmidt B, Weinberg CR, Weitzel JN, Wendt C, Wolk A, Yadav S, Yang XR, Yannoukakos D, Zheng W, Ziogas A, Zorn KK, Park SK, Thomassen M, Offit K, Schmutzler RK, Couch FJ, Simard J, Chenevix-Trench G, Easton DF, Andrieu N, Antoniou AC. Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nat Commun. 2021 May 14;12(1):2986. doi: 10.1038/s41467-021-23162-4. PMID: 33990587; PMCID: PMC8121813.
Copy Download .nbib Format: NLM
Endometrial cancer may be part of the MUTYH-associated polyposis cancer spectrum.

European journal of medical genetics

Villy MC, Masliah-Planchon J, Buecher B, Beaulaton C, Vincent-Salomon A, Stoppa-Lyonnet D, Colas C.
PMID: 34775073
Eur J Med Genet. 2022 Jan;65(1):104385. doi: 10.1016/j.ejmg.2021.104385. Epub 2021 Nov 11.

The MUTYH gene encodes a DNA glycosylase that prevents G:C→T:A transversions. Patients with biallelic pathogenic germline MUTYH variants develop an adenomatous polyposis called MUTYH-associated polyposis (MAP). Endometrial cancers have been reported in patients with MAP, but the role of...

Cite
Villy MC, Masliah-Planchon J, Buecher B, et al. Endometrial cancer may be part of the MUTYH-associated polyposis cancer spectrum. Eur J Med Genet. 2021;65(1):104385doi: 10.1016/j.ejmg.2021.104385.
Villy, M. C., Masliah-Planchon, J., Buecher, B., Beaulaton, C., Vincent-Salomon, A., Stoppa-Lyonnet, D., & Colas, C. (2022). Endometrial cancer may be part of the MUTYH-associated polyposis cancer spectrum. European journal of medical genetics, 65(1), 104385. https://doi.org/10.1016/j.ejmg.2021.104385
Villy, Marie-Charlotte, et al. "Endometrial cancer may be part of the MUTYH-associated polyposis cancer spectrum." European journal of medical genetics vol. 65,1 (2022): 104385. doi: https://doi.org/10.1016/j.ejmg.2021.104385
Villy MC, Masliah-Planchon J, Buecher B, Beaulaton C, Vincent-Salomon A, Stoppa-Lyonnet D, Colas C. Endometrial cancer may be part of the MUTYH-associated polyposis cancer spectrum. Eur J Med Genet. 2022 Jan;65(1):104385. doi: 10.1016/j.ejmg.2021.104385. Epub 2021 Nov 11. PMID: 34775073.
Copy Download .nbib Format: NLM
Highly Sensitive Detection Method of DICER1 Tumor Hotspot Mutations by Drop-off Droplet Digital PCR.

Clinical chemistry

Vibert R, Gauthier-Villars M, Carrière C, Dubois d'Enghien C, Cyrta J, Vincent-Salomon A, Stoppa-Lyonnet D, Bièche I, Jeannot E, Golmard L.
PMID: 34928333
Clin Chem. 2021 Dec 20; doi: 10.1093/clinchem/hvab248. Epub 2021 Dec 20.

BACKGROUND: DICER1 syndrome is an autosomal dominant inherited syndrome predisposing to various benign and malignant tumors, mainly occurring in children and young adults, requiring broad surveillance starting at birth with repeated irradiating imaging exams and sedations for young patients....

Cite
Vibert R, Gauthier-Villars M, Carrière C, et al. Highly Sensitive Detection Method of DICER1 Tumor Hotspot Mutations by Drop-off Droplet Digital PCR. Clin Chem. 2021;doi: 10.1093/clinchem/hvab248.
Vibert, R., Gauthier-Villars, M., Carrière, C., Dubois d'Enghien, C., Cyrta, J., Vincent-Salomon, A., Stoppa-Lyonnet, D., Bièche, I., Jeannot, E., & Golmard, L. (2021). Highly Sensitive Detection Method of DICER1 Tumor Hotspot Mutations by Drop-off Droplet Digital PCR. Clinical chemistry, . https://doi.org/10.1093/clinchem/hvab248
Vibert, Roseline, et al. "Highly Sensitive Detection Method of DICER1 Tumor Hotspot Mutations by Drop-off Droplet Digital PCR." Clinical chemistry vol. (2021). doi: https://doi.org/10.1093/clinchem/hvab248
Vibert R, Gauthier-Villars M, Carrière C, Dubois d'Enghien C, Cyrta J, Vincent-Salomon A, Stoppa-Lyonnet D, Bièche I, Jeannot E, Golmard L. Highly Sensitive Detection Method of DICER1 Tumor Hotspot Mutations by Drop-off Droplet Digital PCR. Clin Chem. 2021 Dec 20; doi: 10.1093/clinchem/hvab248. Epub 2021 Dec 20. PMID: 34928333.
Copy Download .nbib Format: NLM
Endometrial cancer may be part of the MUTYH-associated polyposis cancer spectrum.

European journal of medical genetics

Villy MC, Masliah-Planchon J, Buecher B, Beaulaton C, Vincent-Salomon A, Stoppa-Lyonnet D, Colas C.
PMID: 34775073
Eur J Med Genet. 2021 Nov 11;65(1):104385. doi: 10.1016/j.ejmg.2021.104385. Epub 2021 Nov 11.

The MUTYH gene encodes a DNA glycosylase that prevents G:C→T:A transversions. Patients with biallelic pathogenic germline MUTYH variants develop an adenomatous polyposis called MUTYH-associated polyposis (MAP). Endometrial cancers have been reported in patients with MAP, but the role of...

Cite
Villy MC, Masliah-Planchon J, Buecher B, et al. Endometrial cancer may be part of the MUTYH-associated polyposis cancer spectrum. Eur J Med Genet. 2021;65(1):104385doi: 10.1016/j.ejmg.2021.104385.
Villy, M. C., Masliah-Planchon, J., Buecher, B., Beaulaton, C., Vincent-Salomon, A., Stoppa-Lyonnet, D., & Colas, C. (2021). Endometrial cancer may be part of the MUTYH-associated polyposis cancer spectrum. European journal of medical genetics, 65(1), 104385. https://doi.org/10.1016/j.ejmg.2021.104385
Villy, Marie-Charlotte, et al. "Endometrial cancer may be part of the MUTYH-associated polyposis cancer spectrum." European journal of medical genetics vol. 65,1 (2021): 104385. doi: https://doi.org/10.1016/j.ejmg.2021.104385
Villy MC, Masliah-Planchon J, Buecher B, Beaulaton C, Vincent-Salomon A, Stoppa-Lyonnet D, Colas C. Endometrial cancer may be part of the MUTYH-associated polyposis cancer spectrum. Eur J Med Genet. 2021 Nov 11;65(1):104385. doi: 10.1016/j.ejmg.2021.104385. Epub 2021 Nov 11. PMID: 34775073.
Copy Download .nbib Format: NLM
BRCA1-p53 relationship in hereditary breast cancer.

International journal of oncology

Sobol H, Stoppalyonnet D, Bressacdepaillerets B, Peyrat J, Guinebretiere J, Jacquemier J, Eisinger F, Birnbaum D.
PMID: 21533383
Int J Oncol. 1997 Feb;10(2):349-53. doi: 10.3892/ijo.10.2.349.

BRCA1, a major gene predisposing to breast and ovarian cancers, encodes a ring finger-containing protein. Its function is still unknown. Recently, the existence of a new structural domain called BRCT was postulated. This domain has some similarity with the...

Cite
Sobol H, Stoppalyonnet D, Bressacdepaillerets B, et al. BRCA1-p53 relationship in hereditary breast cancer. Int J Oncol. 1997;10(2):349-53doi: 10.3892/ijo.10.2.349.
Sobol, H., Stoppalyonnet, D., Bressacdepaillerets, B., Peyrat, J., Guinebretiere, J., Jacquemier, J., Eisinger, F., & Birnbaum, D. (1997). BRCA1-p53 relationship in hereditary breast cancer. International journal of oncology, 10(2), 349-53. https://doi.org/10.3892/ijo.10.2.349
Sobol, H, et al. "BRCA1-p53 relationship in hereditary breast cancer." International journal of oncology vol. 10,2 (1997): 349-53. doi: https://doi.org/10.3892/ijo.10.2.349
Sobol H, Stoppalyonnet D, Bressacdepaillerets B, Peyrat J, Guinebretiere J, Jacquemier J, Eisinger F, Birnbaum D. BRCA1-p53 relationship in hereditary breast cancer. Int J Oncol. 1997 Feb;10(2):349-53. doi: 10.3892/ijo.10.2.349. PMID: 21533383.
Copy Download .nbib Format: NLM
Hormone replacement therapy after prophylactic adnexectomy.

Hereditary cancer in clinical practice

This P, Salmon RJ, Dolbeault S, de la Rochefordière A, Sigal-Zafrani B, Stoppa-Lyonnet D.
PMID: 20223046
Hered Cancer Clin Pract. 2005 Sep 15;3(4):181-2. doi: 10.1186/1897-4287-3-4-181.

No abstract available.

Cite
This P, Salmon RJ, Dolbeault S, et al. Hormone replacement therapy after prophylactic adnexectomy. Hered Cancer Clin Pract. 2005;3(4):181-2doi: 10.1186/1897-4287-3-4-181.
This, P., Salmon, R. J., Dolbeault, S., de la Rochefordière, A., Sigal-Zafrani, B., Stoppa-Lyonnet, D. (2005). Hormone replacement therapy after prophylactic adnexectomy. Hereditary cancer in clinical practice, 3(4), 181-2. https://doi.org/10.1186/1897-4287-3-4-181
This, Pascale, et al. "Hormone replacement therapy after prophylactic adnexectomy." Hereditary cancer in clinical practice vol. 3,4 (2005): 181-2. doi: https://doi.org/10.1186/1897-4287-3-4-181
This P, Salmon RJ, Dolbeault S, de la Rochefordière A, Sigal-Zafrani B, Stoppa-Lyonnet D. Hormone replacement therapy after prophylactic adnexectomy. Hered Cancer Clin Pract. 2005 Sep 15;3(4):181-2. doi: 10.1186/1897-4287-3-4-181. PMID: 20223046; PMCID: PMC2837062.
Copy Download .nbib Format: NLM
First international workshop of the ATM and cancer risk group (4-5 December 2019).

Familial cancer

Lesueur F, Easton DF, Renault AL, Tavtigian SV, Bernstein JL, Kote-Jarai Z, Eeles RA, Plaseska-Karanfia D, Feliubadaló L, Arun B, Herold N, Versmold B, Schmutzler RK, Nguyen-Dumont T, Southey MC, Dorling L, Dunning AM, Ghiorzo P, Dalmasso BS, Cavaciuti E, Le Gal D, Roberts NJ, Dominguez-Valentin M, Rookus M, Taylor AMR, Goldstein AM, Goldgar DE, Stoppa-Lyonnet D, Andrieu N.
PMID: 34125377
Fam Cancer. 2021 Jun 14; doi: 10.1007/s10689-021-00248-y. Epub 2021 Jun 14.

The first International Workshop of the ATM and Cancer Risk group focusing on the role of Ataxia-Telangiectasia Mutated (ATM) gene in cancer was held on December 4 and 5, 2019 at Institut Curie in Paris, France. It was motivated...

Cite
Lesueur F, Easton DF, Renault AL, et al. First international workshop of the ATM and cancer risk group (4-5 December 2019). Fam Cancer. 2021;doi: 10.1007/s10689-021-00248-y.
Lesueur, F., Easton, D. F., Renault, A. L., Tavtigian, S. V., Bernstein, J. L., Kote-Jarai, Z., Eeles, R. A., Plaseska-Karanfia, D., Feliubadaló, L., Arun, B., Herold, N., Versmold, B., Schmutzler, R. K., Nguyen-Dumont, T., Southey, M. C., Dorling, L., Dunning, A. M., Ghiorzo, P., Dalmasso, B. S., Cavaciuti, E., Le Gal, D., Roberts, N. J., Dominguez-Valentin, M., Rookus, M., Taylor, A. M. R., Goldstein, A. M., Goldgar, D. E., Stoppa-Lyonnet, D., & Andrieu, N. (2021). First international workshop of the ATM and cancer risk group (4-5 December 2019). Familial cancer, . https://doi.org/10.1007/s10689-021-00248-y
Lesueur, Fabienne, et al. "First international workshop of the ATM and cancer risk group (4-5 December 2019)." Familial cancer vol. (2021). doi: https://doi.org/10.1007/s10689-021-00248-y
Lesueur F, Easton DF, Renault AL, Tavtigian SV, Bernstein JL, Kote-Jarai Z, Eeles RA, Plaseska-Karanfia D, Feliubadaló L, Arun B, Herold N, Versmold B, Schmutzler RK, Nguyen-Dumont T, Southey MC, Dorling L, Dunning AM, Ghiorzo P, Dalmasso BS, Cavaciuti E, Le Gal D, Roberts NJ, Dominguez-Valentin M, Rookus M, Taylor AMR, Goldstein AM, Goldgar DE, Stoppa-Lyonnet D, Andrieu N. First international workshop of the ATM and cancer risk group (4-5 December 2019). Fam Cancer. 2021 Jun 14; doi: 10.1007/s10689-021-00248-y. Epub 2021 Jun 14. PMID: 34125377.
Copy Download .nbib Format: NLM
GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in .

Frontiers in oncology

Lesueur F, Mebirouk N, Jiao Y, Barjhoux L, Belotti M, Laurent M, Léone M, Houdayer C, Bressac-de Paillerets B, Vaur D, Sobol H, Noguès C, Longy M, Mortemousque I, Fert-Ferrer S, Mouret-Fourme E, Pujol P, Venat-Bouvet L, Bignon YJ, Leroux D, Coupier I, Berthet P, Mari V, Delnatte C, Gesta P, Collonge-Rame MA, Giraud S, Bonadona V, Baurand A, Faivre L, Buecher B, Lasset C, Gauthier-Villars M, Damiola F, Mazoyer S, Caputo SM, Andrieu N, Stoppa-Lyonnet D.
PMID: 30430080
Front Oncol. 2018 Oct 31;8:490. doi: 10.3389/fonc.2018.00490. eCollection 2018.

No abstract available.

Cite
Lesueur F, Mebirouk N, Jiao Y, et al. GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in . Front Oncol. 2018;8:490doi: 10.3389/fonc.2018.00490.
Lesueur, F., Mebirouk, N., Jiao, Y., Barjhoux, L., Belotti, M., Laurent, M., Léone, M., Houdayer, C., Bressac-de Paillerets, B., Vaur, D., Sobol, H., Noguès, C., Longy, M., Mortemousque, I., Fert-Ferrer, S., Mouret-Fourme, E., Pujol, P., Venat-Bouvet, L., Bignon, Y. J., Leroux, D., Coupier, I., Berthet, P., Mari, V., Delnatte, C., Gesta, P., Collonge-Rame, M. A., Giraud, S., Bonadona, V., Baurand, A., Faivre, L., Buecher, B., Lasset, C., Gauthier-Villars, M., Damiola, F., Mazoyer, S., Caputo, S. M., Andrieu, N., Stoppa-Lyonnet, D. (2018). GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in . Frontiers in oncology, 8490. https://doi.org/10.3389/fonc.2018.00490
Lesueur, Fabienne, et al. "GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in ." Frontiers in oncology vol. 8 (2018): 490. doi: https://doi.org/10.3389/fonc.2018.00490
Lesueur F, Mebirouk N, Jiao Y, Barjhoux L, Belotti M, Laurent M, Léone M, Houdayer C, Bressac-de Paillerets B, Vaur D, Sobol H, Noguès C, Longy M, Mortemousque I, Fert-Ferrer S, Mouret-Fourme E, Pujol P, Venat-Bouvet L, Bignon YJ, Leroux D, Coupier I, Berthet P, Mari V, Delnatte C, Gesta P, Collonge-Rame MA, Giraud S, Bonadona V, Baurand A, Faivre L, Buecher B, Lasset C, Gauthier-Villars M, Damiola F, Mazoyer S, Caputo SM, Andrieu N, Stoppa-Lyonnet D. GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in . Front Oncol. 2018 Oct 31;8:490. doi: 10.3389/fonc.2018.00490. eCollection 2018. PMID: 30430080; PMCID: PMC6220051.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 42 entries